Is echocardiography mandatory for all *Streptococcus gallolyticus* bacteremia?

**CURRENT STATUS:** UNDER REVIEW

**BMC Infectious Diseases**

Worapong Nasomsong  
Phramongkutklao Hospital  
*ORCiD:* [https://orcid.org/0000-0002-3486-8591](https://orcid.org/0000-0002-3486-8591)

Vasin Vasikasin  
Phramongkutklao Hospital

Jantima Traipattanakul  
Phramongkutklao Hospital

Dhitiwat Changpradub  
*Corresponding Author*  
*ORCiD:* [https://orcid.org/0000-0001-7939-6834](https://orcid.org/0000-0001-7939-6834)

**DOI:**  
[10.21203/rs.2.20799/v2](10.21203/rs.2.20799/v2)

**SUBJECT AREAS**  
*Infectious Diseases*  
*Cardiac & Cardiovascular Systems*

**KEYWORDS**  
*Streptococcus gallolyticus subspecies pasteurianus, endocarditis*
Abstract
Background: Streptococcus gallolyticus, formerly known as one of the Streptococcus bovis group, is frequently associated with endocarditis. Current guidelines recommended diagnostic work-up for endocarditis among patients with S. gallolyticus bacteremia. However, S. gallolyticus subsp. pasteurianus, was found to be associated with neonatal sepsis and liver diseases and is less commonly associated with endocarditis compared with S. gallolyticus subsp. gallolyticus. Our study aimed to identify the risk factors for S. gallolyticus subsp. pasteurianus endocarditis to help select the patients for echocardiography. Methods: In this retrospective cohort study, medical records from all adult patients with S. gallolyticus subsp. pasteurianus isolated from blood cultures at Phramongkutklao Hospital from 2009 to 2015 were reviewed. Patients who had mixed bacteremia or missing records were excluded from the study. Result: During the study period, S. gallolyticus subsp. pasteurianus were isolated among 106 individuals. Mean age was 66.9±15.6 years. Most patients (61.3%) were male, with cirrhosis as the most common underlying diseases (46.2%), followed by malignancy and chronic kidney disease. Most common manifestations included primary bacteremia (44.3%), followed by spontaneous bacterial peritonitis (23.6%). Infective endocarditis was found among 9 patients. No patients with cirrhosis or single blood specimen of bacteremia had endocarditis (RR 0; p-value 0.003, and RR 1.35; p-value 0.079). The common complications associated with endocarditis were acute respiratory failure (RR 4.32; p-value 0.05), whereas acute kidney injury was a protective factor (RR 0; p-value 0.01). Among 76 patients who had records of 2-year follow-up, no new diagnosis of endocarditis or malignancy was observed. Conclusion: Among patients with S. gallolyticus subsp. pasteurianus bacteremia, echocardiography might not be needed among patients with cirrhosis or transient bacteremia. Key word: Streptococcus gallolyticus subspecies pasteurianus, endocarditis.

Background
Formerly, Streptococcus bovis was known as a common pathogen for infective endocarditis, usually associated with colorectal neoplasia. (1, 2) However, taxonomy and nomenclature of S. bovis was recently distinguished using a molecular method, such as 16s rRNA gene and sodA gene, in six
different DNA groups. Common human pathogenic subspecies include \textit{S. gallolyticus} subsp. \textit{gallolyticus} (formerly \textit{S. bovis} biotype I), \textit{S. gallolyticus} subsp. \textit{pasteurianus} (formerly \textit{S. bovis} biotype II/2), \textit{S. infantarius} subsp. \textit{infantarius} and \textit{S. infantarius} subsp. \textit{coli}. (2-6)

Since the introduction of the new taxonomic classification, the disparity of clinical syndromes and patient’s underlying diseases between the two subspecies were observed. \textit{S. gallolyticus} subsp. \textit{gallolyticus} bacteremia was strongly associated with endocarditis and colorectal neoplasia (7, 8). Nevertheless, \textit{S. gallolyticus} subsp. \textit{pasteurianus} was found to be associated with neonatal sepsis, liver diseases and malignancies of the digestive tract, i.e., gastric, pancreatic, hepatobiliary and colorectal cancer and is less commonly associated with endocarditis (14-23%) compared with \textit{S. gallolyticus} subsp. \textit{gallolyticus} (50-53%). (9-15) Nevertheless, many guidelines still recommend diagnostic work-up for endocarditis in all \textit{S. gallolyticus} bacteremia cases, which may result in unnecessary procedures and higher costs of hospitalization. (16, 17)

Because of the lack of large-scale studies investigating the association between \textit{S. gallolyticus} subsp. \textit{pasteurianus} and endocarditis, we aimed to find the risk factors for \textit{S. gallolyticus} subsp. \textit{pasteurianus} endocarditis to help select appropriate patients for echocardiography, expected to minimize the unnecessary investigation.

\textbf{Objectives}

Our primary objective was to determine the risk factors for developing endocarditis among patients with \textit{S. gallolyticus} subsp. \textit{pasteurianus} bacteremia and secondary objective was to determine the 30-day mortality rate of \textit{S. gallolyticus} subsp. \textit{pasteurianus} bacteremia

\textbf{Methods}

\textbf{Study setting and design}

A retrospective cohort study was conducted. We collected all blood isolates of \textit{S. gallolyticus} subsp. \textit{pasteurianus} obtained from patients from April 2009 to May 2015 at Phramongkutklao Hospital, a 1200 bed teaching hospital of Phramongkutklao College of Medicine, Royal Thai Army, Bangkok, Thailand. The inclusion criteria were participants aged over 18 years with monomicrobial \textit{S. gallolyticus} subsp. \textit{pasteurianus} bacteremia. Participants referred to other hospitals within the first
seven days were excluded. Demographic data, patient characteristics, comorbidities, immunosuppressive status, microbiological data and patient outcomes were recorded. The site of infection was defined according to definitions of the Centers for Disease Control and Prevention. (18) Patients whose foci of infection were unidentified were classified as primary bacteremia. Results from echocardiography, ultrasonography, computed tomography and endoscopic examinations searching for endocarditis, hepatobiliary pathology and colonic lesions were collected. All-cause-30-day crude mortality after the onset of bacteremia was recorded. Participants’ medical records were followed up to two years focusing on the finding of new malignancy or endocarditis. The study protocol followed the guidelines of the Declaration of Helsinki and ethics approval was obtained from the Institutional Review Board, Royal Thai army Department.

**Microbiological analysis**

Bacterial isolates were collected by the clinical microbiological laboratory at the study hospital. Species were identified using the BACTEC system (Becton Dickson, Sparks, MD). The VITEK 2 automated system (bio-Merieux, Hazelwood, MO) was used to identify bacterial and subspecies. Antimicrobial susceptibility was determined using the disk diffusion test of various antimicrobial agents including penicillin, gentamicin, clindamycin, ceftriaxone, erythromycin, azithromycin, moxifloxacin, levofloxacin, tigecycline, linezolid, daptomycin and vancomycin. Minimum inhibitory concentrations (MICs) of the isolates to penicillin and ceftriaxone were performed using the E-test. Disk diffusion and MICs were interpreted using the Clinical and Laboratory Standards Institute (CLSI) guidelines. (19)

**Statistical analysis**

For categorical variables, Fisher’s exact test and the Chi-square test were used. The Mann-Whitney test was used to compare continuous variables. For all analyses, a two-sided p-value of 0.05 was considered significant. Potentially significant predictors in the univariate analyses (p-value <0.10) were included in a forward, stepwise multiple logistic regression model to identify the most important factors related to developing endocarditis. All statistical analyses were performed using Stata 12.0 Software (StataCorp, USA).
Results
During the study period, *S. gallolyticus* subsp. *pasteurianus* was isolated in 106 individuals, in whom 191 specimens (88%) blood culture specimens were positive among the overall of 217 specimens taken. The mean age was 66.9±15.6 years. Most patients were male (61.3%), with cirrhosis as the most common underlying disease, followed by diabetes mellitus, malignancy, and chronic kidney disease. Nearly 20% of participants had experienced a malignancy before bacteremic episodes. The most common malignancies included hepatocellular carcinoma, colorectal cancer and hematologic malignancy. The most common clinical manifestations comprised primary bacteremia, followed by spontaneous bacterial peritonitis and endocarditis. Acute kidney injury, septic shock, and respiratory failure were the three most common complications. Almost all participants had bacteria isolated in two blood culture specimens. The 30-day crude mortality rate was 21.7%, and baseline characteristics of all participants are shown in the Table 1.

Thirty-five patients underwent echocardiography based on clinical presentation and physician decision as Figure 1. Nine patients were diagnosed with infective endocarditis as described in Table 2. All of whom had positive blood culture in more than two specimens (RR 1.35; p-value 0.079). None of the cirrhosis patients had endocarditis (RR 0; p-value 0.003). The common complication associated with endocarditis was acute respiratory failure (RR 4.32; p-value 0.05), whereas acute kidney injury served as a protective factor (RR 0; p-value 0.01) as shown in Table 3. Because of the small number of patients with endocarditis, multivariate analysis was not performed.

Among 76 patients with records of two-year follow-up, no new diagnosis of endocarditis or malignancy was observed.

The majority of *S. gallolyticus* subsp. *pasteurianus* was susceptible to antimicrobial agents, with penicillin susceptibility at 97%. However, a high rate of erythromycin resistance (24.5%) was observed as shown in the Table 4.

Discussion
In this cohort study, nearly one half of the patients with *S. gallolyticus* subsp. *pasteurianus* bacteremia presented cirrhosis. This finding was consistent with those of related studies reporting
that 15 to 39% of patients had liver diseases or cirrhosis. (8, 14, 15)

Regarding the clinical presentations, this study was consistent with others reporting primary bacteremia as the most common clinical presentation, followed by spontaneous bacterial peritonitis, and infective endocarditis. (8, 14, 15) About 20% of participants were diagnosed with malignancy before the onset of bacteremia. As in other studies, a correlation between gastrointestinal and other organ malignancies with the bacteremia could not be demonstrated. (14) Although colonoscopy was performed in only 10% of patients, which might have underestimated the true prevalence of precancerous colorectal lesions, no new malignancy was observed after two years among 76 participants.

With the proportion of 8.5%, endocarditis was still an uncommon finding, similar to what had been reported in related studies. (8, 14) None of the endocarditis patients had cirrhosis, which was demonstrated to be a significantly protective factor. The different pathophysiology and clinical syndromes between cirrhotic and noncirrhotic patients may be explained by the diversity of the bacterial strain regarding the cell attachment ability. Although no study had determined the difference in host-microbe interaction between the two subspecies, the S. gallolyticus endocarditis strain was shown to have the significant capability to adhere to the endothelial cell lining of the human umbilical vein (HUVEC). (20) The cell surface of the blood group antigen sialyl lewis-X (sLex) normally expressed on human leukocytes enabling the rolling of leukocytes on the endothelium, increases the adhesion ability of S. gallolyticus to endothelial cells (21, 22). In contrast, the main origin of bacteremia among patients with cirrhosis arise from the fecal microbiome, which might have inferior virulence and less adhesion ability to the endothelium. (23)

Because S. gallolyticus subsp. pasteurianus, isolated from two or more different blood cultures, is one of the two major Duke criteria raising the suspicion of endocarditis, echocardiography should be performed. (16, 17) From our findings, because of the lower incidence of endocarditis other than S. bovis, this diagnostic procedure might not be needed in patients with cirrhosis, which will decrease the excessive investigation by one half of patients with the bacteremia.

The mortality rate of the bacteremia was higher than related reports. (8, 14) This observation may be
explained by the higher proportion of patients with cirrhosis, which usually had higher complications and mortality rates. (23)

Although some isolates were intermediate or resistant to beta-lactams using disk diffusion tests, all isolates were susceptible after the MIC measurement when E-test method was performed. This error is due to the poor discrimination ability of disc diffusion tests between penicillin-susceptible and penicillin-intermediate streptococcal populations. (24, 25) As a result, MIC measurement should be primarily used to interpret susceptibility results or to confirm resistance in resistant isolates determined by the disk diffusion method.

Although this is the first study to demonstrate a correlation between S. galloyticus subsp. pasteurianus and infective endocarditis among noncirrhotic patients, it had certain limitations. First, although a large number of participants were enrolled in this study, only 8.5% presented endocarditis, which might have overestimated the true association. This small proportion helps confirm that, unlike S. galloyticus subsp. galloyticus, S. galloyticus subsp. pasteurianus uncommonly causes endocarditis. Second, the ability of species identification using VITEK 2 system to discriminate between the two subspecies of S. galloyticus is not apparent. Nevertheless, studies comparing the Vitek 2 and sodA sequencing method showed generally acceptable agreement. (26) Finally, due to the retrospective design, factors influencing the physician’s reason for the decision to perform colonoscopy and echocardiography was unidentified, which might have underestimated the prevalence of endocarditis and cancer. However, this bias was minimized by the long-term follow-up.

Conclusion
Among patients with S. galloyticus subsp. pasteurianus bacteremia, echocardiography might not be needed among patients with cirrhosis and without sustained bacteremia.

Abbreviations
S. bovis: Streptococcus bovis
S. galloyticus: Streptococcus galloyticus
S. galloyticus subsp. galloyticus: S. galloyticus subspecies galloyticus
S. galloyticus subsp. pasteurianus: S. galloyticus subspecies pasteurianus
**MIC**: minimum inhibitory concentrations

**CLSI**: Clinical and Laboratory Standards Institute

**Declaration**

**Ethics approval and consent to participate**

The study protocol followed the guidelines of the Declaration of Helsinki and ethics approval was obtained from the Institutional Review Board, Royal Thai army Department.

The Ethics Committee of the Institutional Review Board, Royal Thai army Department waived the need to obtain consent for the collection, analysis and publication of the retrospectively obtained and anonymized data for this non-interventional study.

**Consent for publication**

Not Applicable

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare no potential conflict of interest relevant to this article existed.

**Funding**

This study was supported by the Division of Infectious Diseases, Department of Internal Medicine, Phramongkutklao Hospital.

The funder supported budget in patient data collection process and all research equipment expenses e.g. office supplies.

**Authors' contributions**

WN prepared proposal, collected the patient data and was a major contributor in writing the manuscript.

VV analyzed and interpreted the patient data regarding to factors related to developing endocarditis in *S. gallolyticus* subsp. *pasteurianus* bacteremia.
J T assisted in patient data collection.

DC supervised the manuscript writing and managed the funding.

All authors read and approved the final manuscript.

Acknowledgements

Not Applicable

References

1. Sharara Al AHT, Malli A, El-Halabi MM, Hashash JG, Ghaith OA et al. Association of Streptococcus bovis endocarditis and advanced colorectal neoplasia: a case-control study. J Dig Dis. 2013;14(7):382-7.

2. Schlegel L GF, Collins MD, Re´gnault B, Grimont PAD, Bouvet A. Streptococcus infantarius, Streptococcus infantarius subsp. infantarius and Streptococcus infantarius subsp. coli isolated from humans and food. Int J Syst Evol Microbiol. 2000; 50:1425–34.

3. R. F. Recognition of group D streptococcal species of human origin by biochemical and physiological tests. Appl Microbiol. 1972; 23:1131–9.

4. Farrow JAE KJ, Phillips BA, Bramley AJ, Collins MD. Taxonomic studies on Streptococcus bovis and Streptococcus equinus: description of Streptococcus galactolyticus and Streptococcus saccharolyticus. Syst Appl Microbiol. 1984; 5:467–82.

5. Osawa R FT, Sly LI. Streptococcus galloyticus sp. gallate degrading organisms formerly assigned to Streptococcus bovis. Syst Appl Microbiol. 1995; 18:74–8.

6. Beck M FR, Funke G. Comprehensive study of strains previously designated Streptococcus bovis consecutively isolated from human blood cultures and emended description of Streptococcus galloyticus and Streptococcus infantarius subsp. coli. J Clin Microbiol. 2008; 46:2966–72.

7. Boleij A vGM, Swinkels DW, Tjalsma H. Clinical importance of Streptococcus
galloyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infc Dis 2011;53(9):870-8.

8. Lazarovitch T SM, Levine M, Brusovansky R, Akins R, Hayakawa K. The relationship between the new taxonomy of Streptococcus bovis and its clonality to colon cancer, endocarditis, and biliary disease. Infection. 2013; 41:329-37.

9. Biarc J NI, Pini A, et al. Carcinogenic properties of proteins with pro-inflammatory activity from Streptococcus infantarius (formerly S. bovis). Carcinogenesis. 2004; 25:1477-84.

10. J Corredoira J AM, García-Garrote F, García-Pais MJ, Coira A, Rabuñal R et al. Streptococcus bovis group and biliary tract infections: an analysis of 51 cases. Clin Microbiol Infect. 2014; 20:405-9.

11. McCoy WC MJ. Enterococcal endocarditis associated with carcinoma of the sigmoid: report of a case. J Med Assoc State Ala. 1951; 21:162-6.

12. Nopjaroonsri P LA, Chayakulkeeree M. Clinical characteristics of Group D Streptococcal Bacteremia in Siriraj Hospital. Proceedings of the 39th Thailand Infectious Disease Annual Conference Infectious Diseases Progress 2013; Chiang Mai, Thailand, 2013.

13. Romero B, Morosini, M. I., Loza, E., Rodríguez-Baños, M., Navas, E., Cantón, R., & Campo, R. D. Reidentification of Streptococcus bovis isolates causing bacteremia according to the new taxonomy criteria: still an issue. J Clin Microbiol. 2011;49(9):3228-33.

14. Sheng WH CY, Teng LJ, Hsueh PR. Bacteraemia due to Streptococcus galloyticus subspecies pasteurianus is associated with digestive tract malignancies and resistance to macrolides and clindamycin. J Infect. 2014;69(2):145-53.

15. Tripodi MF AL, Ragone E, Durante Mangoni E, Fortunato R, Iarussi D et al.
*Streptococcus bovis* endocarditis and its association with chronic liver disease: an underestimated risk factor. Clin Infect Dis. 2004;38(10):1394-400.

16. Baddour LM WW, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals from the American Heart Association. Circulation. 2015;132(15):1435-86.

17. Habib G LP, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;21(44):3075-128.

18. Garner JS JW, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16(3):128e40.

19. Clinical and Laboratory Standard Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement. CLSI document M100-MS20 [Internet]. 2012. Available from: https://clsi.org.

20. Jans C BA. The road to infection: host-microbe interactions defining the pathogenicity of *Streptococcus bovis/Streptococcus equinus* complex members. Front Microbiol. 2018;10(9):603.

21. Hirota K, Osawa, R., Nemoto, K., Ono, T., and Miyake Y. Highly expressed human sialyl Lewis antigen on cell surface of *Streptococcus galloyticus*. Lancet. 1996; 347:760.

22. Vollmer T, Hinse, D., Kleesiek, K., and Dreier, J. Interactions between endocarditis-derived *Streptococcus galloyticus* subsp. *galloyticus* isolates and human endothelial cells. BMC Microbiol. 2010; 10:78.
23. Bunchorntavakul C CN, Chavalitdhamrong D. Bacterial infections in cirrhosis: a critical review and practical guidance. World J Hepatol. 2016;8(6):307–21.

24. National Committee for Clinical Laboratory Standards Performance Standards for Antimicrobial Susceptibility Testing, Fifteenth Information Supplement M100-S15. NCCLS [Internet]. 2005. Available from: https://clsi.org/.

25. Streit JM SJ, Thorne GM, Alder J, Jones RN. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. J Antimicrob Chemother. 2005;55(4):574-8.

26. Dekker JP, Lau AF. An update on the Streptococcus bovis Group: classification, identification, and disease associations. J Clin Microbiol. 2016;54(7):1694-9.

Tables
Table 1: Baseline characteristics of all S. galolyticus subsp. pasteurianus bacteremic participants
| Characteristic                                      | N   |
|---------------------------------------------------|-----|
| Male                                              | 65/106 |
| Age (mean (SD), years)                            | 66.9 (15.7) |
| Underlying disease                                | 100/106 |
| Cirrhosis                                         | 49/106 |
| Diabetes                                          | 32/106 |
| Chronic kidney disease/ ESRD                      | 26/106 |
| Neurovascular disease                             | 11/106 |
| Hematologic disease                               | 9/106 |
| Biliary stone                                     | 6/106 |
| Chronic liver disease                             | 4/106 |
| Autoimmune disease                                | 4/106 |
| Others                                            | 17/106 |
| Malignancy diagnosed before presentation          | 20/106 |
| Hepatocellular carcinoma                          | 7/20 |
| Colorectal cancer                                 | 6/20 |
| Hematologic malignancy                            | 2/20 |
| Others                                            | 5/20 |
| Clinical syndrome                                 |       |
| Primary bacteremia                                | 47/106 |
| Spontaneous bacterial peritonitis                 | 25/106 |
| Endocarditis                                      | 9/106 |
| Intraabdominal infection                          | 4/106 |
| Biliary tract infection                           | 4/106 |
| Skin and soft tissue infection                    | 4/106 |
| CNS infection                                     | 4/106 |
| Other clinical syndromes                          | 9/106 |
| Complications                                     |       |
| Acute kidney injury                               | 43/106 |
| Septic shock                                      | 40/106 |
| Respiratory failure                               | 11/106 |
| Multiorgan failure                                | 9/106 |
| DIC                                               | 7/106 |
| Number of positive specimens                      |       |
| ≥2 specimens                                      | 81/106 |
| Echocardiography performed                        | 35/106 |
| Colonoscopy performed                             | 11/106 |
| 30-day mortality rate                             | 23/106 |
| Length of hospital stay (median (IQR), days)      | 12 (6-22) |

Table 2: Characteristics of nine patients with endocarditis
| Case | Age(yrs.)/sex | Underlying disease | Modified Duke's criteria Major / Minor criteria | Valve | Treatment |
|------|-------------|--------------------|-----------------------------------------------|-------|-----------|
| 1    | 71/male     | Diabetes           | 2 / 1                                          | Aortic | Ceftriaxone |
| 2    | 43/male     | ESRD* Lymphoma     | 2 / 1                                          | Mitral | PGS*      |
| 3    | 72/male     | Cerebrovascular disease | 2 / 2                                          | Mitral | PGS*      |
| 4    | 80/male     | Hypertension       | 2 / 2                                          | Aortic | Ceftriaxone |
| 5    | 78/male     | Dyslipidemia       | 2 / 2                                          | Aortic | Ceftriaxone |
| 6    | 44/male     | None               | 2 / 2                                          | Aortic | PGS*      |
| 7    | 84/male     | Diabetes Colonic cancer | 2 / 2                                          | Mitral | PGS*      |
| 8    | 70/female   | Hypertension       | 2 / 3                                          | Aortic | PGS*      |
| 9    | 51/female   | ESRD*              | 1 / 3                                          | Aortic | Ceftriaxone |

* PGS = penicillin G sodium, ESRD = End stage renal disease

Table 3: Univariate analysis of factors associated with infective endocarditis in S. gallolyticus subsp. pasteurianus bacteremia
Table 4: Susceptibility data of 106 isolates of *S. gallolyticus* subsp. *pasteurianus*

| Antimicrobial agent | Disk diffusion test | Epsilometer |
|---------------------|---------------------|-------------|
|                     | Susceptible | Intermediate | Resistance | MIC range (ug/mL) | M (ug) |
| Penicillin          | 103         | 97.2         | 3          | 2.8                | 0      |
|                     | No.         | %            | No.        | %                  |        |
| Ceftriaxone         | 97          | 91.5         | 2          | 1.9                | 7      |
|                     |             |              | No.        | %                  | 0.09-0.75 | 0   |
| Levofloxacin        | 89          | 84.0         | 6          | 5.7                | 11     |
|                     |             |              | No.        | %                  | N/A    | Φ   |
| Chloramphenicol     | 101         | 95.3         | 2          | 1.9                | 3      |
|                     |             |              | No.        | %                  | N/A    | Φ   |
| Erythromycin        | 26          | 24.5         | 0          | 0                  | 80     |
|                     |             |              | No.        | %                  | 75.5   | N/A | Φ   |
| Vancomycin          | 106         | 100.0        | 0          | 0                  | 0      |
|                     |             |              | No.        | %                  | N/A    | Φ   |
| Linezolid           | 106         | 100.0        | 0          | 0                  | 0      |
|                     |             |              | No.        | %                  | N/A    | Φ   |